

Evry, December 8th, 2003

ObeTherapy Strengthens Its Drug Discovery Capabilities with Key Management Appointments Evry, France, December 2003

New recruits will allow ObeTherapy to realize the full potential research program on obesity, diabetes type II and dyslipidemia.

ObeTherapy announced today the recruitment of two important new members to its scientific team. Dr. Sébastien Barradeau joins ObeTherapy from Aventis Pharma, Center for Functional Genomics, Germany, and has been appointed head of HTS and drug discovery research at ObeTherapy. Dr. Bénédicte Fournés previously spent four years at the McGill Cancer Centre in Montreal, Canada, and has been appointed head of target validation.

We are pleased to welcome Dr. Sébastien Barradeau and Dr. Bénédicte Fournés to ObeTherapy. Dr. Barradeau did his PhD in Institut Pasteur, France, and has several years of experience working in Aventis Pharma. His expertise in establishing biochemical and cellular assays adaptable for HTS and his knowledge in drug discovery will strengthen our experience in this domain. Dr. Fournés has many years of practice in molecular and cellular biology and in the use of transgenic animal models. Dr. Fournés is responsible on our program of target validation using transgenic rabbit as an animal model in collaboration with Prof. Louis-Marie Houdebine from INRA in Jouy-en-Josas explained Chief Executive Officer Dr. Itzik Harosh founder of ObeTherapy.

Contact: Dr. Itzik Harosh, Founder and CSO
Tel. 33-160878904
Fax. 33-160878999
E. mail : iharosh@obetherapy.com

<http://www.obetherapy.com>